Congress Targets Six Trump Administration Regulations for Elimination Under the CRA
The Democrat-led Congress has targeted six Trump-era regulations for elimination under the Congressional Review Act.
All Publications
Developing Regulatory Alternatives Through Early Input
Agencies face a multitude of requirements instituted by Congress and the president to guide their rulemaking procedures. In some cases, these laws and orders, such as Executive Order 12866 and the Regulatory Flexibility Act, mandate that the agency consider a variety of regulatory approaches when developing a rule.
A Project Worth Watching at OIRA
Building up the ability for agencies to conduct effective benefit-cost analysis was difficult when President Clinton authored Executive Order 12866 in 1993, so too will be building out better distributional analysis under President Biden’s “Modernizing Regulatory Review” Memorandum. It was worth the effort then, and it will be worth the effort now.
Seismic Shift In The Regulatory Tide
The first two months of the Biden-Harris administration indicate a departure from the traditional regulatory review practices embraced by both parties.
Where are the Congressional Review Act Disapprovals?
The stars are aligned for Democrats to use the Congressional Review Act (CRA) to disapprove federal agency regulations from the end of the Trump administration. But will they? With an April 4 deadline looming, members of Congress are running out of time to get the process started with the introduction of a resolution to disapprove a rule.
Beyond Republicans and the Disapproval of Regulations
This article finds that the Congressional Review Act has become an institutionalized instrument of oversight of regulatory policymaking.
The General Services Administration updated the classic version of Regulations.gov, the primary website used for accepting public comments.
Regulatory Benefit-Cost Analysis—Advice for a New Presidential Term
SBCA organized a panel dispensing advice to the incoming Biden administration on improving and expanding the use of benefit-cost analysis.
Telemedicine & Initiating Buprenorphine Treatment
Federal regulators dramatically reduced the barriers to using telemedicine to treat opioid use disorder in response to the COVID-19 public health emergency. Public health experts have long argued that health care practitioners can provide high-quality treatment for opioid use disorder via telemedicine. Until now, federal regulation has limited the ability of practitioners to prescribe buprenorphine, one of the medications considered the gold standard for treatment of opioid use disorder, using telemedicine.